The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1506588
The Antitumor Mechanisms of Glabridin and Drug Delivery Strategies for Enhancing Its Bioavailability
Provisionally accepted
Chong Li
1
Yu Wang
1*
Wen Jing Zhang
1
Xiaoman Yang
1*
Yufang Wang
1*
Guanqun Hou
1*
Dongli Wang
2*
Bingbing Han
1*
Yimin Zhang
1*- 1 College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
- 2 Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
Glabridin, a flavonoid derived from the plant Glycyrrhiza glabra, has garnered significant attention due to its diverse pharmacological effects, including antioxidant, antibacterial, anti-inflammatory, hypolipidemic, and hypoglycemic activities. Studies have shown that glabridin exhibits substantial antitumor activity by modulating the proliferation, apoptosis, metastasis, and invasion of cancer cells through the targeting of various signaling pathways, thus indicating its potential as a therapeutic agent for malignant tumors. To enhance its solubility, stability, and bioavailability, several drug delivery systems have been developed, including liposomes, cyclodextrin inclusion complexes, nanoparticles, and polymeric micelles. These delivery systems have shown promise in preclinical studies but face challenges in clinical translation, such as issues with biocompatibility, delivery efficiency, and long-term stability. A comprehensive analysis of the antitumor mechanism of glabridin and its novel drug delivery system is still lacking. Therefore, the authors performed a comprehensive review of recent literature on the antitumor effects of glabridin and its novel drug delivery systems, covering the antitumor mechanism, action targets, and novel drug delivery systems, offering new theoretical insights and development directions for its further advancement and clinical application.
Keywords: glabridin, antitumor, Novel Delivery System, Mechanism, Safety evaluation
Received: 05 Oct 2024; Accepted: 22 Nov 2024.
Copyright: © 2024 Li, Wang, Zhang, Yang, Wang, Hou, Wang, Han and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yu Wang, College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
Xiaoman Yang, College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
Yufang Wang, College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
Guanqun Hou, College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
Dongli Wang, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong Province, China
Bingbing Han, College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
Yimin Zhang, College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.